Peanut Allergy Targeted By DBV Technologies As It Raises $55 Million In Second Euro Biotech IPO This Year

France's DBV Technologies lists on NYSE Euronext in Paris and targets peanut and other food allergies for the first clinical studies of its epicutaneous patches as allergy desensitization therapies.